{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:24:04Z","timestamp":1793229844757,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroImage: Clinical"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.nicl.2023.103347","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T18:55:09Z","timestamp":1676141709000},"page":"103347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Longitudinal DAT changes measured with [18F]FE-PE2I PET in patients with Parkinson\u2019s disease; a validation study"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5770-8419","authenticated-orcid":false,"given":"V.S.","family":"Kerstens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sundgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brumberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Halldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Varrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.nicl.2023.103347_b0005","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1177\/0271678X20958755","article-title":"Simplified quantification of [18F]FE-PE2I PET in Parkinson\u2019s disease: Discriminative power, test\u2013retest reliability and longitudinal validity during early peak and late pseudo-equilibrium","volume":"41","author":"Brumberg","year":"2021","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.nicl.2023.103347_b0010","doi-asserted-by":"crossref","unstructured":"Burciu, R. G., Ofori, E., Archer, D. B., Wu, S. S., Pasternak, O., McFarland, N. R., \u2026 Vaillancourt, D. E. (2017). Progression marker of Parkinson\u2019s disease: a 4-year multi-site imaging study. Brain, 140(8), 2183\u20132192. https:\/\/doi.org\/10.1093\/BRAIN\/AWX146.","DOI":"10.1093\/brain\/awx146"},{"key":"10.1016\/j.nicl.2023.103347_b0015","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.nicl.2017.03.011","article-title":"Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson\u2019s disease","volume":"14","author":"Caminiti","year":"2017","journal-title":"NeuroImage. Clinical"},{"issue":"6","key":"10.1016\/j.nicl.2023.103347_b0020","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00006231-200106000-00017","article-title":"Striatal dopamine transporter binding in early to moderately advanced parkinson\u2019s disease: Monitoring of disease progression over 2 years","volume":"22","author":"Chouker","year":"2001","journal-title":"Nuclear Medicine Communications"},{"issue":"4","key":"10.1016\/j.nicl.2023.103347_b0025","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.neuroimage.2006.02.053","article-title":"A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635","volume":"32","author":"Csel\u00e9nyi","year":"2006","journal-title":"NeuroImage."},{"key":"10.1016\/j.nicl.2023.103347_b0030","doi-asserted-by":"crossref","unstructured":"Derringer, J. (2018). A simple correction for non-independent tests. https:\/\/doi.org\/10.31234\/OSF.IO\/F2TYW.","DOI":"10.31234\/osf.io\/f2tyw"},{"issue":"5","key":"10.1016\/j.nicl.2023.103347_b0035","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2967\/jnumed.114.152421","article-title":"Quantitative Analysis of 18F-(E)-N-(3-Iodoprop-2-Enyl)-2\u03b2-Carbofluoroethoxy-3\u03b2-(4\u2019-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease","volume":"56","author":"Fazio","year":"2015","journal-title":"Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine"},{"issue":"4","key":"10.1016\/j.nicl.2023.103347_b0040","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.27316","article-title":"Nigrostriatal dopamine transporter availability in early Parkinson\u2019s disease","volume":"33","author":"Fazio","year":"2018","journal-title":"Movement Disorders"},{"issue":"12","key":"10.1016\/j.nicl.2023.103347_b0045","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2169\/internalmedicine.2489-18","article-title":"Dopamine transporter imaging in parkinson disease: Progressive changes and therapeutic modification after anti-parkinsonian medications","volume":"58","author":"Ikeda","year":"2019","journal-title":"Internal Medicine."},{"issue":"6","key":"10.1016\/j.nicl.2023.103347_b0050","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ana.25103","article-title":"Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies","volume":"82","author":"Kaasinen","year":"2017","journal-title":"Annals of Neurology."},{"issue":"1","key":"10.1016\/j.nicl.2023.103347_b0055","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-020-00676-4","article-title":"Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson\u2019s disease","volume":"10","author":"Kerstens","year":"2020","journal-title":"EJNMMI Research"},{"issue":"5","key":"10.1016\/j.nicl.2023.103347_b0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40336-020-00386-w","article-title":"Dopamine transporter imaging in neurodegenerative movement disorders: PET vs","volume":"8","author":"Kerstens","year":"2020","journal-title":"SPECT. Clinical and Translational Imaging"},{"issue":"12","key":"10.1016\/j.nicl.2023.103347_b0065","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1021\/acsmedchemlett.8b00504","article-title":"In Vitro Ligand Binding Kinetics Explains the Pharmacokinetics of [18 F]FE-PE2I in Dopamine Transporter PET Imaging","volume":"9","author":"Kukk","year":"2018","journal-title":"ACS Medicinal Chemistry Letters."},{"issue":"NOV","key":"10.1016\/j.nicl.2023.103347_b0070","first-page":"863","article-title":"Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs","volume":"4","author":"Lakens","year":"2013","journal-title":"Frontiers in Psychology"},{"issue":"3","key":"10.1016\/j.nicl.2023.103347_b0075","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.hdy.6800717","article-title":"Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix","volume":"95","author":"Li","year":"2005","journal-title":"Heredity"},{"issue":"1","key":"10.1016\/j.nicl.2023.103347_b0080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.27183","article-title":"11C-PE2I and 18F-Dopa PET for assessing progression rate in Parkinson\u2019s: A longitudinal study","volume":"33","author":"Li","year":"2018","journal-title":"Movement Disorders."},{"issue":"8","key":"10.1016\/j.nicl.2023.103347_b0085","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2967\/jnumed.117.197186","article-title":"Whole-body biodistribution and dosimetry of the dopamine transporter Radioligand 18 F-FE-PE2I in human subjects","volume":"59","author":"Lizana","year":"2018","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.nicl.2023.103347_b0090","unstructured":"Marek, K, Seibyl, J., Caspell-Garcia, C., Coffey, C., Mollenhauer, B., Kieburtz, K., \u2026 Simuni, T. (2018). PPMI driven sample size estimation for clinical trials in Parkinson\u2019s disease. Retrieved February 9, 2022, from https:\/\/www.mdsabstracts.org\/abstract\/ppmi-driven-sample-size-estimation-for-clinical-trials-in-parkinsons-disease\/%0Ahttp:\/\/ovidsp.ovid.com\/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed19&AN=624550616 https:\/\/ucl-new-primo.hosted.exlibrisgroup.c."},{"issue":"13","key":"10.1016\/j.nicl.2023.103347_b0095","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/jama.287.13.1653","article-title":"Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression","volume":"287","author":"Marek","year":"2002","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.nicl.2023.103347_b0100","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","article-title":"EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0","volume":"47","author":"Morbelli","year":"2020","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.nicl.2023.103347_b0105","doi-asserted-by":"crossref","unstructured":"Nandhagopal, R., Kuramoto, L., Schulzer, M., Mak, E., Cragg, J., McKenzie, J., \u2026 Stoessl, A. J. (2011). Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson\u2019s disease. Brain. 134(Pt 11):3290-8. https:\/\/doi.org\/10.1093\/brain\/awr233.","DOI":"10.1093\/brain\/awr233"},{"issue":"3","key":"10.1016\/j.nicl.2023.103347_b0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/JPD-171092","article-title":"Glucocerebrosidase Mutations in Parkinson Disease","volume":"7","author":"O\u2019Regan","year":"2017","journal-title":"Journal of Parkinson\u2019s Disease."},{"issue":"1","key":"10.1016\/j.nicl.2023.103347_b0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/JPD-191710","article-title":"Longitudinal Change of DAT SPECT in Parkinson\u2019s Disease and Multiple System Atrophy","volume":"10","author":"Sakakibara","year":"2020","journal-title":"Journal of Parkinson\u2019s Disease"},{"issue":"7","key":"10.1016\/j.nicl.2023.103347_b0120","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2967\/jnumed.111.101626","article-title":"Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I","volume":"53","author":"Sasaki","year":"2012","journal-title":"Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine"},{"issue":"16","key":"10.1016\/j.nicl.2023.103347_b0125","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1016\/j.bmcl.2009.06.032","article-title":"Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter","volume":"19","author":"Schou","year":"2009","journal-title":"Bioorganic and Medicinal Chemistry Letters."},{"issue":"5","key":"10.1016\/j.nicl.2023.103347_b0130","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s007020070077","article-title":"Measuring the progression of idiopathic Parkinson\u2019s disease with [123I] \u03b2-CIT SPECT","volume":"107","author":"Staffen","year":"2000","journal-title":"Journal of Neural Transmission"},{"issue":"6","key":"10.1016\/j.nicl.2023.103347_b0135","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jlcr.2927","article-title":"An efficient one-step radiosynthesis of [18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters","volume":"55","author":"Stepanov","year":"2012","journal-title":"Journal of Labelled Compounds and Radiopharmaceuticals"},{"issue":"35","key":"10.1016\/j.nicl.2023.103347_b0140","article-title":"Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[b- 11 C]DOPA and [18 F]FE-PE2I in humans. Nucl Med Commun Wolters Kluwer Health","volume":"35","author":"Suzuki","year":"2014","journal-title":"Nuclear Medicine Communications"},{"issue":"10","key":"10.1016\/j.nicl.2023.103347_b0145","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00259-009-1156-3","article-title":"Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT","volume":"36","author":"Varrone","year":"2009","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"1","key":"10.1016\/j.nicl.2023.103347_b0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2967\/jnumed.110.077651","article-title":"Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I","volume":"52","author":"Varrone","year":"2011","journal-title":"Journal of Nuclear Medicine."},{"issue":"8\u20139","key":"10.1016\/j.nicl.2023.103347_b0160","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s007020170019","article-title":"[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson\u2019s disease","volume":"108","author":"Winogrodzka","year":"2001","journal-title":"J Neural Transm."}],"container-title":["NeuroImage: Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158223000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158223000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:30:35Z","timestamp":1781105435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213158223000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":31,"alternative-id":["S2213158223000360"],"URL":"https:\/\/doi.org\/10.1016\/j.nicl.2023.103347","relation":{},"ISSN":["2213-1582"],"issn-type":[{"value":"2213-1582","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal DAT changes measured with [18F]FE-PE2I PET in patients with Parkinson\u2019s disease; a validation study","name":"articletitle","label":"Article Title"},{"value":"NeuroImage: Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nicl.2023.103347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Karolinska Institutet. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103347"}}